WallStSmart

nVent Electric PLC (NVT)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 208% more annual revenue ($12.00B vs $3.89B). VRTX leads profitability with a 32.9% profit margin vs 18.2%. NVT appears more attractively valued with a PEG of 1.57. NVT earns a higher WallStSmart Score of 67/100 (B-).

NVT

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 7.0Value: 8.7Quality: 5.0

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVTUndervalued (+10.8%)

Margin of Safety

+10.8%

Fair Value

$126.36

Current Price

$116.98

$9.38 discount

UndervaluedFair: $126.36Overvalued
VRTXUndervalued (+39.5%)

Margin of Safety

+39.5%

Fair Value

$716.04

Current Price

$433.07

$282.97 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVT1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
41.8%10/10

Revenue surging 41.8% year-over-year

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

NVT2 concerns · Avg: 3.0/10
PEG RatioValuation
1.574/10

Expensive relative to growth rate

P/E RatioValuation
46.5x2/10

Premium valuation, high expectations priced in

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVT

The strongest argument for NVT centers on Revenue Growth. Profitability is solid with margins at 18.2% and operating margin at 16.2%. Revenue growth of 41.8% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : NVT

The primary concerns for NVT are PEG Ratio, P/E Ratio. A P/E of 46.5x leaves little room for execution misses.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

NVT profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.

NVT carries more volatility with a beta of 1.30 — expect wider price swings.

NVT is growing revenue faster at 41.8% — sustainability is the question.

VRTX generates stronger free cash flow (349M), providing more financial flexibility.

Bottom Line

NVT scores higher overall (67/100 vs 66/100), backed by strong 18.2% margins and 41.8% revenue growth. VRTX offers better value entry with a 39.5% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

nVent Electric PLC

INDUSTRIALS · ELECTRICAL EQUIPMENT & PARTS · USA

nVent Electric plc designs, manufactures, markets, installs and services electrical connection and protection products in the United States, Canada, Western and Eastern Europe included in the European Union, China, Eastern Europe not included in the European Union, America Latin, Middle East, Southeast Asia, Australia and Japan. The company is headquartered in London, the United Kingdom.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?